Hazard ratio (with 95% confidence interval) of duration of smoking and of duration of smoking cessation for mortality from all causes, CVD, COPD, and any specific types of cancer.

<p>Hazard ratio (with 95% confidence interval) of duration of smoking and of duration of smoking cessation for mortality from all causes, CVD, COPD, and any specific types of cancer.</p

Hazard ratio (with 95% confidence interval) of lifetime smoking habits for mortality from all causes, CVD, COPD, any and specific types of cancer among all 3925 subjects.

<p>Hazard ratio (with 95% confidence interval) of lifetime smoking habits for mortality from all causes, CVD, COPD, any and specific types of cancer among all 3925 subjects.</p

Characteristics at baseline in the general population of Vlagtwedde-Vlaardingen, stratified by vital status after 40 years of follow-up (n = 8465).

<p>Characteristics at baseline in the general population of Vlagtwedde-Vlaardingen, stratified by vital status after 40 years of follow-up (n = 8465).</p

Hazard ratio (with 95% confidence interval) of smoking habits at baseline for mortality from all-causes, CVD, COPD, any and specific types of cancer, among all 7074 subjects.

<p>Hazard ratio (with 95% confidence interval) of smoking habits at baseline for mortality from all-causes, CVD, COPD, any and specific types of cancer, among all 7074 subjects.</p

Distribution of genotypes and hazard ratio (HR) for all-cause mortality.

*<p>Due to the low frequency of individuals being homozygous for the minor allele heterozygotes and homozygotes variants were combined</p>**<p>Differences in genotype distribution between alive subjects and those who died (excluding external causes of death) tested with χ² test</p>***<p>Cox regression adjusted for age, gender and packyears at visit in 1989/90</p

Survival curves for all-cause mortality according to SNP rs12778366.

<p><b>a</b>. all subjects; <b>b</b>. stratified according to gender; <b>c</b>. stratified according to smoking habits; <b>d</b>. stratified according to BMI; <b>e</b>. stratified according to age (median age at visit in 1989/1900). *the Y axis scale in a <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0058636#pone-0058636-g001" target="_blank">figure 1e</a> differs from Y axis scales in other figures.</p

Hazard ratio (with 95% confidence interval) of smoking habits including pipe/cigar smoking for mortality from all causes, CVD, COPD, any and specific types of cancer, among 3480 males for the analyses on baseline and among 2067 males for the analyses on lifetime smoking habits.

<p>Hazard ratio (with 95% confidence interval) of smoking habits including pipe/cigar smoking for mortality from all causes, CVD, COPD, any and specific types of cancer, among 3480 males for the analyses on baseline and among 2067 males for the analyses on lifetime smoking habits.</p

HR for all-cause mortality for rs12778366 TC+CC genotypes in stratified analysis.

*<p>n = number of all subjects included in the analysis (excluding those who died due to external causes)</p>**<p>rs12778366 TT genotype as a reference</p

Glucose levels (mmol/l) measured in males after the oral glucose tolerance test (OGGT).

*<p>Regression coefficient (B), its standard error (SE) and p value obtained with linear regression analysis adjusted for age at the measurement.</p

Distribution of genotypes according to all-cause and cause-specific mortality.

*<p>Differences between alive subjects and those who died (excluding external causes of death) tested with χ² test.</p>**<p>Differences between alive subjects and those who died due to COPD tested with χ² test.</p>***<p>Differences between alive subjects and those who died due to CVD tested with χ² test.</p